Evidence map›Paper›PMID 39078014›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2024

Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case Report

Kongfei Li, Yuxiao Wang, Renzhi Pei, Ying Lu, Junjie Cao, Xianxu Zhuang, Jiaying Lian, Bibo Zhang

Abstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kongfei LiThe Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, ChinaORCID 0000-0001-7938-3224
Yuxiao WangThe Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, ChinaORCID 0009-0000-3854-2890
Renzhi PeiThe Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, ChinaORCID 0009-0008-2630-4762
Ying LuThe Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, ChinaORCID 0000-0002-2509-9209
Junjie CaoThe Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, ChinaORCID 0000-0003-0997-4293
Xianxu ZhuangThe Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, ChinaORCID 0009-0003-1307-472X
Jiaying LianThe Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, ChinaORCID 0009-0004-7099-8790
Bibo ZhangThe Affiliated People’s Hospital of Ningbo University, Department of Hematology, Ningbo, ChinaORCID 0000-0003-2031-0359

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, HeterocyclicInotuzumab OzogamicinSulfonamidesAminoglycosidesAntibodies, Monoclonal, HumanizedHumansLeukemia, Biphenotypic, AcuteMaleMiddle AgedSialic Acid Binding Ig-like Lectin 2AminoglycosidesAntibodies, Monoclonal, HumanizedAzacitidineBridged Bicyclo Compounds, HeterocyclicCD22 protein, humanInotuzumab OzogamicinSialic Acid Binding Ig-like Lectin 2SulfonamidesvenetoclaxInotuzumab ozogamicinMixed-phenotype acute leukemiaTargeted therapy

Identifiers

PMID39078014
PMCPMC11589369

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.